Rocket Lab (RKLB) saw RKLB stock drop more than 11% on March 18 after announcing plans for a $1 billion stock sale, reigniting fears of additional dilution following the completion of a $749 million equity sale under a prior at-the-market facility. However, the selloff was quickly followed by a major new contract win: a $190 million U.S. Department of War agreement for 20 hypersonic test flights using its HASTE launch vehicle. This marks the single-largest launch contract in the company’s history and catapults its total backlog across launch services and space systems past the $2 billion mark.
While dilution concerns are undeniably real for shareholders, Rocket Lab's rapidly expanding business momentum and record backlog raise a key question. Is the growth trajectory still worth the risk?
